Studies will be carried out to determine the feasibility of the first National State Laboratory of Molecules, Genetics and Health Prototypes in Honduras with the support of CABEI
Technical cooperation in the amount of US$357,500 will be used to formulate studies for the design, construction and equipment of the institution, which will have the capacity to produce pharmaceuticals and health prototypes, among others.
Mérida, Yucatan, September 23, 2022.- With the objective of improving coverage and access to health services for the benefit of Hondurans, the Central American Bank for Economic Integration (CABEI) and the Government of the Republic of Honduras formalized this Friday a contingent recovery technical cooperation for US$357,500 to carry out the design, construction, equipment and start-up studies for the National Laboratory of Biological Molecules, Genetics and Health Prototypes.
This would be a state institution capable of producing medicines, vaccines, reagents, prototypes and prostheses, paternity, sequencing and cytogenetic tests, among others, which will strengthen the public health network of the Republic of Honduras.
CABEI's Executive President, Dr. Dante Mossi, said: "We are pleased to be able to contribute to the human development of Honduras by strengthening the health system to guarantee a quality service to safeguard the wellbeing of Hondurans, while at the same time reducing public spending given the local production of medicines that would be produced in this innovative laboratory.”
The consultancy will be executed within six months and, based on the results obtained, the Government of the Republic of Honduras may request CABEI financing for the investment project.
This initiative is part of CABEI's 2020-2024 Institutional Strategy, aimed at improving the efficiency of human capital through investment in health and education in favor of labor productivity.
